author_facet Aldosary, F.
Tremblay, P.
Hébert, C.
Blier, P.
Aldosary, F.
Tremblay, P.
Hébert, C.
Blier, P.
author Aldosary, F.
Tremblay, P.
Hébert, C.
Blier, P.
spellingShingle Aldosary, F.
Tremblay, P.
Hébert, C.
Blier, P.
Clinical & Investigative Medicine
Atomoxetine, but not paroxetine, blocks norepinephrine reuptake in depressed patientss
General Medicine
author_sort aldosary, f.
spelling Aldosary, F. Tremblay, P. Hébert, C. Blier, P. 1488-2353 University of Toronto Libraries - UOTL General Medicine http://dx.doi.org/10.25011/cim.v30i4.2838 <jats:p>Purpose: Paroxetine is a potent serotonin (5-HT) reuptake inhibitor. However, a purported norepinephrine (NE) reuptake blockade action remains to be established. Atomoxetine is a potent NE reuptake inhibitor with the indication of attention deficit hyperactivity disorder (ADHD). The present study was aimed at confirming a NE reuptake inhibitory action with ascending doses of atomoxetine and possibly with paroxetine in depressed patients. &#x0D; Methods: Patients were randomized to escalating doses of either paroxetine (20 to 50 mg/day), or atomoxetine (25-80 mg/day) in a four to six week period. Inhibition of NE reuptake was assessed using the attenuation of systolic blood pressure (SBP) elevations produced by intravenous injections of tyramine. Tyramine penetrates into peripheral NE terminals via the NE reuptake transporter and releases NE. Then, NE acts on the vascular adrenoceptors, which causes an elevation of SBP. Drugs that block NE reuptake attenuate the pressor effects of tyramine. Two-way ANOVA for repeated measures for doses of tyramine and treatments were used to assess the effects of the different drug regimens on the pressor response to loads of 3–6 mg of tyramine. Sixteen patients with unipolar major depressive disorder were assessed weekly after increasing the dose of paroxetine (9 patients) and atomoxetine (7 patients). &#x0D; Results: Atomoxetine exerted a robust inhibition of the tyramine response, starting at the dose of 25mg/day in a dose-dependent pattern. Neither the low nor the high doses of paroxetine altered the tyramine pressor response. &#x0D; Conclusions: These results provide evidence that atomoxetine started significantly inhibiting NE reuptake at subtherapeutic dose for ADHD, whereas paroxetine leaves the activity of the NE transporter unaltered, even at the highest recommended dose for depression.</jats:p> Atomoxetine, but not paroxetine, blocks norepinephrine reuptake in depressed patientss Clinical & Investigative Medicine
doi_str_mv 10.25011/cim.v30i4.2838
facet_avail Online
Free
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMjUwMTEvY2ltLnYzMGk0LjI4Mzg
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMjUwMTEvY2ltLnYzMGk0LjI4Mzg
institution DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
DE-L229
imprint University of Toronto Libraries - UOTL, 2007
imprint_str_mv University of Toronto Libraries - UOTL, 2007
issn 1488-2353
issn_str_mv 1488-2353
language Undetermined
mega_collection University of Toronto Libraries - UOTL (CrossRef)
match_str aldosary2007atomoxetinebutnotparoxetineblocksnorepinephrinereuptakeindepressedpatientss
publishDateSort 2007
publisher University of Toronto Libraries - UOTL
recordtype ai
record_format ai
series Clinical & Investigative Medicine
source_id 49
title Atomoxetine, but not paroxetine, blocks norepinephrine reuptake in depressed patientss
title_unstemmed Atomoxetine, but not paroxetine, blocks norepinephrine reuptake in depressed patientss
title_full Atomoxetine, but not paroxetine, blocks norepinephrine reuptake in depressed patientss
title_fullStr Atomoxetine, but not paroxetine, blocks norepinephrine reuptake in depressed patientss
title_full_unstemmed Atomoxetine, but not paroxetine, blocks norepinephrine reuptake in depressed patientss
title_short Atomoxetine, but not paroxetine, blocks norepinephrine reuptake in depressed patientss
title_sort atomoxetine, but not paroxetine, blocks norepinephrine reuptake in depressed patientss
topic General Medicine
url http://dx.doi.org/10.25011/cim.v30i4.2838
publishDate 2007
physical 72
description <jats:p>Purpose: Paroxetine is a potent serotonin (5-HT) reuptake inhibitor. However, a purported norepinephrine (NE) reuptake blockade action remains to be established. Atomoxetine is a potent NE reuptake inhibitor with the indication of attention deficit hyperactivity disorder (ADHD). The present study was aimed at confirming a NE reuptake inhibitory action with ascending doses of atomoxetine and possibly with paroxetine in depressed patients. &#x0D; Methods: Patients were randomized to escalating doses of either paroxetine (20 to 50 mg/day), or atomoxetine (25-80 mg/day) in a four to six week period. Inhibition of NE reuptake was assessed using the attenuation of systolic blood pressure (SBP) elevations produced by intravenous injections of tyramine. Tyramine penetrates into peripheral NE terminals via the NE reuptake transporter and releases NE. Then, NE acts on the vascular adrenoceptors, which causes an elevation of SBP. Drugs that block NE reuptake attenuate the pressor effects of tyramine. Two-way ANOVA for repeated measures for doses of tyramine and treatments were used to assess the effects of the different drug regimens on the pressor response to loads of 3–6 mg of tyramine. Sixteen patients with unipolar major depressive disorder were assessed weekly after increasing the dose of paroxetine (9 patients) and atomoxetine (7 patients). &#x0D; Results: Atomoxetine exerted a robust inhibition of the tyramine response, starting at the dose of 25mg/day in a dose-dependent pattern. Neither the low nor the high doses of paroxetine altered the tyramine pressor response. &#x0D; Conclusions: These results provide evidence that atomoxetine started significantly inhibiting NE reuptake at subtherapeutic dose for ADHD, whereas paroxetine leaves the activity of the NE transporter unaltered, even at the highest recommended dose for depression.</jats:p>
container_issue 4
container_start_page 0
container_title Clinical & Investigative Medicine
container_volume 30
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792326622374789133
geogr_code not assigned
last_indexed 2024-03-01T12:24:12.844Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Atomoxetine%2C+but+not+paroxetine%2C+blocks+norepinephrine+reuptake+in+depressed+patientss&rft.date=2007-08-01&genre=article&issn=1488-2353&volume=30&issue=4&pages=72&jtitle=Clinical+%26+Investigative+Medicine&atitle=Atomoxetine%2C+but+not+paroxetine%2C+blocks+norepinephrine+reuptake+in+depressed+patientss&aulast=Blier&aufirst=P.&rft_id=info%3Adoi%2F10.25011%2Fcim.v30i4.2838&rft.language%5B0%5D=und
SOLR
_version_ 1792326622374789133
author Aldosary, F., Tremblay, P., Hébert, C., Blier, P.
author_facet Aldosary, F., Tremblay, P., Hébert, C., Blier, P., Aldosary, F., Tremblay, P., Hébert, C., Blier, P.
author_sort aldosary, f.
container_issue 4
container_start_page 0
container_title Clinical & Investigative Medicine
container_volume 30
description <jats:p>Purpose: Paroxetine is a potent serotonin (5-HT) reuptake inhibitor. However, a purported norepinephrine (NE) reuptake blockade action remains to be established. Atomoxetine is a potent NE reuptake inhibitor with the indication of attention deficit hyperactivity disorder (ADHD). The present study was aimed at confirming a NE reuptake inhibitory action with ascending doses of atomoxetine and possibly with paroxetine in depressed patients. &#x0D; Methods: Patients were randomized to escalating doses of either paroxetine (20 to 50 mg/day), or atomoxetine (25-80 mg/day) in a four to six week period. Inhibition of NE reuptake was assessed using the attenuation of systolic blood pressure (SBP) elevations produced by intravenous injections of tyramine. Tyramine penetrates into peripheral NE terminals via the NE reuptake transporter and releases NE. Then, NE acts on the vascular adrenoceptors, which causes an elevation of SBP. Drugs that block NE reuptake attenuate the pressor effects of tyramine. Two-way ANOVA for repeated measures for doses of tyramine and treatments were used to assess the effects of the different drug regimens on the pressor response to loads of 3–6 mg of tyramine. Sixteen patients with unipolar major depressive disorder were assessed weekly after increasing the dose of paroxetine (9 patients) and atomoxetine (7 patients). &#x0D; Results: Atomoxetine exerted a robust inhibition of the tyramine response, starting at the dose of 25mg/day in a dose-dependent pattern. Neither the low nor the high doses of paroxetine altered the tyramine pressor response. &#x0D; Conclusions: These results provide evidence that atomoxetine started significantly inhibiting NE reuptake at subtherapeutic dose for ADHD, whereas paroxetine leaves the activity of the NE transporter unaltered, even at the highest recommended dose for depression.</jats:p>
doi_str_mv 10.25011/cim.v30i4.2838
facet_avail Online, Free
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMjUwMTEvY2ltLnYzMGk0LjI4Mzg
imprint University of Toronto Libraries - UOTL, 2007
imprint_str_mv University of Toronto Libraries - UOTL, 2007
institution DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229
issn 1488-2353
issn_str_mv 1488-2353
language Undetermined
last_indexed 2024-03-01T12:24:12.844Z
match_str aldosary2007atomoxetinebutnotparoxetineblocksnorepinephrinereuptakeindepressedpatientss
mega_collection University of Toronto Libraries - UOTL (CrossRef)
physical 72
publishDate 2007
publishDateSort 2007
publisher University of Toronto Libraries - UOTL
record_format ai
recordtype ai
series Clinical & Investigative Medicine
source_id 49
spelling Aldosary, F. Tremblay, P. Hébert, C. Blier, P. 1488-2353 University of Toronto Libraries - UOTL General Medicine http://dx.doi.org/10.25011/cim.v30i4.2838 <jats:p>Purpose: Paroxetine is a potent serotonin (5-HT) reuptake inhibitor. However, a purported norepinephrine (NE) reuptake blockade action remains to be established. Atomoxetine is a potent NE reuptake inhibitor with the indication of attention deficit hyperactivity disorder (ADHD). The present study was aimed at confirming a NE reuptake inhibitory action with ascending doses of atomoxetine and possibly with paroxetine in depressed patients. &#x0D; Methods: Patients were randomized to escalating doses of either paroxetine (20 to 50 mg/day), or atomoxetine (25-80 mg/day) in a four to six week period. Inhibition of NE reuptake was assessed using the attenuation of systolic blood pressure (SBP) elevations produced by intravenous injections of tyramine. Tyramine penetrates into peripheral NE terminals via the NE reuptake transporter and releases NE. Then, NE acts on the vascular adrenoceptors, which causes an elevation of SBP. Drugs that block NE reuptake attenuate the pressor effects of tyramine. Two-way ANOVA for repeated measures for doses of tyramine and treatments were used to assess the effects of the different drug regimens on the pressor response to loads of 3–6 mg of tyramine. Sixteen patients with unipolar major depressive disorder were assessed weekly after increasing the dose of paroxetine (9 patients) and atomoxetine (7 patients). &#x0D; Results: Atomoxetine exerted a robust inhibition of the tyramine response, starting at the dose of 25mg/day in a dose-dependent pattern. Neither the low nor the high doses of paroxetine altered the tyramine pressor response. &#x0D; Conclusions: These results provide evidence that atomoxetine started significantly inhibiting NE reuptake at subtherapeutic dose for ADHD, whereas paroxetine leaves the activity of the NE transporter unaltered, even at the highest recommended dose for depression.</jats:p> Atomoxetine, but not paroxetine, blocks norepinephrine reuptake in depressed patientss Clinical & Investigative Medicine
spellingShingle Aldosary, F., Tremblay, P., Hébert, C., Blier, P., Clinical & Investigative Medicine, Atomoxetine, but not paroxetine, blocks norepinephrine reuptake in depressed patientss, General Medicine
title Atomoxetine, but not paroxetine, blocks norepinephrine reuptake in depressed patientss
title_full Atomoxetine, but not paroxetine, blocks norepinephrine reuptake in depressed patientss
title_fullStr Atomoxetine, but not paroxetine, blocks norepinephrine reuptake in depressed patientss
title_full_unstemmed Atomoxetine, but not paroxetine, blocks norepinephrine reuptake in depressed patientss
title_short Atomoxetine, but not paroxetine, blocks norepinephrine reuptake in depressed patientss
title_sort atomoxetine, but not paroxetine, blocks norepinephrine reuptake in depressed patientss
title_unstemmed Atomoxetine, but not paroxetine, blocks norepinephrine reuptake in depressed patientss
topic General Medicine
url http://dx.doi.org/10.25011/cim.v30i4.2838